• Yasunobu Abe, Motoaki Shiratsuchi, Eriko Nagasawa, Rie Ohtsuka, Junichi Kiyasu, Eriko Sada, Kensaku Idutsu, Kazuhiro Kotoh, Junji Nishimura, Shouichi Ohga, and Ryoichi Takayanagi.
• Department of Medicine and Bioregulatory Science, Graduate School of Medical Sciences, Kyushu University.
• Rinsho Ketsueki. 2010 Jan 1;51(1):74-9.

AbstractEpstein-Barr virus-associated hemophagocytic lymphohistiocytosis (EBV-HLH) is more common in children, and is characterized by pancytopenia, liver dysfunction and coagulopathy caused by interactions between EBV-infected T cells and activated macrophages. We describe here five adults with EBV-HLH. The median age was 17 years (range 16 approximately 40). HLH developed in 4 patients within 2 months after the primary infection, and in the other one during the reactivation. All patients had a high EBV viral load in peripheral blood (2 x 10(2)-3 x 10(6) copies/ml) and monoclonal proliferation of EBV-infected T cells. All patients received immunosuppressive therapy with or without etoposide, and two patients required plasmapheresis due to the severity. Three patients are alive in complete remission (follow up periods; 13, 19, 30 months), while two patients became refractory to chemo-immunotherapy and died despite multidrug chemotherapy. EBV-HLH should be more widely recognized in adults in order to achieve early diagnosis and appropriate treatment.

25 keywords...

hide…